AstraZeneca on track to report Oxford coronavirus vaccine data within a week

British drugmaker AstraZeneca, working with the University of Oxford, is on track to report early data from a late-stage clinical trial of its experimental coronavirus vaccine within a week, said AstraZeneca Egypt chief executive on Tuesday.

Hatem Al-Wardani made these remarks during a press conference in Cairo.

Hopes of the world soon getting an effective vaccine were raised recently after U.S. drugmaker Pfizer and German partner BioNTech announced early this month that their coronavirus vaccine was more than 90 percent effective based on interim trial results. Also Monday, Moderna Inc announced its coronavirus vaccine candidate was 94.5 percent effective.

AstraZeneca had said earlier it has created multiple supply chains to ensure that access to its vaccine is timely, broad and equitable for high- and low-income countries alike. Vaccine data in October showed produces a immune response in both old and young adults.

AstraZeneca had said earlier it has created multiple supply chains to ensure that access to its vaccine is timely, broad and equitable for high- and low-income countries alike.

Pricing and supply of experimental coronavirus vaccines have been widely debated as richer countries inject billions of dollars into funding, and AstraZeneca has also been granted protection from future liability claims.